23.89 USD
▼-0.65-2.65%
盘后 25.45 0.00%
2026-09-15
市值
$3.94B
市盈率
—
EPS
-0.92
股息率
—
52 周区间
6.38 – 34.39
成交量
1.74M
Beta
1.12
目标价
45.18
52W 低 6.3852W 高 34.39
价格走势
公司简介
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ...